Swiss cancer patients face unequal treatment coverage by insurers

  • Share
Swiss cancer patients face unequal treatment coverage by insurers

Swiss cancer patients face unequal treatment coverage by insurers

Cancer patients in Switzerland are experiencing unequal treatment as health insurance companies implement major changes in coverage of innovative drugs and therapies.

This conclusion comes from a report by the Federal Office of Public Health, which RTS (Radio Télévision Suisse Romande) obtained after five years of research, legal proceedings, and access to information.

Analysis of data from 2017–2019 revealed significant variation: some insurers approved 98.2% of requests (such as KPT) while others approved only 45.2% (such as Sanitas).

This disparity primarily affects innovative drugs used off-label—those not automatically covered by insurance. In Switzerland, around 80,000 such requests are submitted annually, each evaluated individually by insurers.

Insurers contest data comparability

Insurance companies argue that direct comparison of data is unfair, as cases are not assessed under the same criteria. However, a reform enacted in 2024 aims to harmonize procedures and reduce costs for these treatments.

Oncologists warn of ongoing inequities

A key response comes from Solange Peters, head of the Oncology Department at the University Hospital of Lausanne. She notes that even between 2020–2025, approval rates for treatment requests varied by more than 20 percentage points.

For example, this month, two pancreatic cancer patients with identical diagnoses and recommended treatments received opposing decisions on cost coverage. This raises concerns about equitable access to medical care and the impact of insurance company choice on treatment opportunities and patient survival.

RTS reports that these cases highlight a deep-rooted issue in Switzerland’s healthcare system, where insurance provider selection can be a critical factor in cancer treatment outcomes.

In brief

Unequal cancer treatment in Switzerland persists, with insurers imposing significant variations in coverage of innovative drugs. Future reforms must aim to standardize procedures and ensure equitable care for all patients.

Notable figures


Source: albinfo.ch
Note: This content has been adapted for informational purposes by Kosova.Today.


2 views 2 sot